Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011; 2(12): 217-220 [PMID: 22174957 DOI: 10.4239/wjd.v2.i12.217]
Corresponding Author of This Article
Diana Boj-Carceller, Dr., Endocrinology and Nutrition Unit, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. dianna_bc@hotmail.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Dec 15, 2011; 2(12): 217-220 Published online Dec 15, 2011. doi: 10.4239/wjd.v2.i12.217
Are proton pump inhibitors a new antidiabetic drug? A cross sectional study
Diana Boj-Carceller, Pilar Bocos-Terraz, Miguel Moreno-Vernis, Alejandro Sanz-Paris, Pablo Trincado-Aznar, Ramón Albero-Gamboa
Diana Boj-Carceller, Alejandro Sanz-Paris, Ramón Albero-Gamboa, Pablo Trincado- Aznar, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain
Pilar Bocos-Terraz, Hormonal Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain
Miguel Moreno-Vernis, Clinical Documentation and Archives Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain
Author contributions: Boj-Carceller D and Bocos-Terraz P conceived and designed the study, performed the analysis and interpretation of data and wrote the manuscript; Moreno-Vernis M collected the data and gave administrative support; Sanz-Paris A, Trincado-Aznar P and Albero-Gamboa R gave a critical revision of the article; all authors approved the version of the manuscript to be published.
Correspondence to: Diana Boj-Carceller, Dr., Endocrinology and Nutrition Unit, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. dianna_bc@hotmail.com
Received: July 4, 2011 Revised: October 2, 2011 Accepted: October 10, 2011 Published online: December 15, 2011
Abstract
AIM: To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabetic patients.
METHODS: A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis of hyperglycemic decompensation, diabetic onset or pregnancy. It compared HbA1c levels of those taking PPIs and those not.
RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to -0.83. People who used PPIs with some type of insulin therapy had a HbA1c reduction by -0.8%, 95% CI: -0.12 to -1.48. For the rest of subgroup analysis based on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels.
CONCLUSION: PPIs seems to be consistently associated with better glycemic control in type 2 diabetes. HbA1c reduction observed is similar to incretin-based therapies.
